Moderna Defies Expectations with Strong Q1 Financials and EU Vaccine Deal, Despite Stock Slump

Cambridge, Massachusetts United States of America
European Union plans to purchase up to 36 million doses of Moderna's Covid vaccine annually for at least four years
Moderna advancing three new vaccine programs (Epstein-Barr virus, Varicella-Zoster virus, norovirus) toward Phase 3 clinical trials
Moderna could win FDA approval for RSV vaccine later this quarter and launch in US this fall
Moderna expects higher vaccination uptake in US if updated Covid vaccine is available with flu shot
Moderna preparing for launches of RSV vaccine and Spikevax 2024-2025 formula, reaffirms sales outlook of $4 billion for 2024
Moderna reports Q1 loss per share of $3.07, lower than projected loss of $3.56
Modern initiates three new clinical studies evaluating investigational individualized neoantigen therapy in combination with Merck's Keytruda for treatment of bladder cancer, kidney cancer and cutaneous squamous cell carcinoma
Sales plummeted to $167 million but surpassed analyst expectations
Moderna Defies Expectations with Strong Q1 Financials and EU Vaccine Deal, Despite Stock Slump

Moderna, the biotech company known for its Covid-19 vaccine, reported stronger-than-expected financial results for the first quarter of 2024. The company's loss per share was $3.07, lower than the projected loss of $3.56 per share by analysts according to FactSet.

Sales plummeted nearly 91% to $167 million, but surpassed analyst expectations of $93 million.

Moderna announced that the European Union plans to purchase up to 36 million doses of its Covid vaccine annually for at least four years. The company also expects higher vaccination uptake in the US if its updated Covid vaccine is available in time with the seasonal flu shot.

The company is preparing for launches of its RSV vaccine and Spikevax 2024-2025 formula, and has reaffirmed its sales outlook of $4 billion for 2024. Moderna could win FDA approval for its RSV vaccine later this quarter and launch it in the US this fall.

Moderna is also advancing three new vaccine programs (Epstein-Barr virus, Varicella-Zoster virus, norovirus) toward Phase 3 clinical trials. The company initiated three new clinical studies evaluating its investigational individualized neoantigen therapy in combination with Merck's Keytruda for treatment of patients with bladder cancer, kidney cancer and cutaneous squamous cell carcinoma.

Despite the positive financial results, Moderna's stock has yet to break out of its year-long slump. The company is facing competition from Pfizer and GSK in the RSV vaccine market.


Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image

Confidence

91%

Doubts
  • Are the sales figures for Q1 accurate?
  • Is the European Union's plan to purchase Moderna's Covid vaccine annually for at least four years a definitive agreement?
  • Will Moderna's updated Covid vaccine be available in time with the seasonal flu shot in the US?

Sources

97%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold

CNBC News Annika Kim Thursday, 02 May 2024 10:35
  • Unique Points
    • European Union plans to buy up to 36 million doses of Moderna’s Covid vaccine annually for at least four years.
    • Moderna retains its outlook for $4 billion in sales of respiratory vaccines, weighted to the back half of 2024.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

97%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Moderna posts quarterly sales beat, smaller loss than expected

Yahoo Finance Patrick Thursday, 02 May 2024 13:46
  • Unique Points
    • Moderna intends to file for approval of its flu vaccine with regulators this year.
  • Accuracy
    • ]Moderna reported quarterly revenue of $167 million, which was lower than the previous year but higher than expected.[
    • Sales of Moderna’s COVID-19 vaccine Spikevax dropped 91% from the previous year.
    • Moderna reaffirmed that it expects to receive approval for its RSV vaccine in time for it to be included in this fall’s U.S. vaccine campaign.
    • Moderna posted a smaller-than-expected loss of $3.07 per share.
    • Analysts expect Moderna’s COVID shot to bring in $3.73 billion and its RSV vaccine to make $166.67 million in 2024.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Moderna Puts Up Big Quarterly Beat; Could Shares Break Out?

Investors.com Financial News Site Analysis - Comprehensive Report on Market Coverage and Analysis - Overall Rating: 90/100 (Highly Reliable, Informative, and Engaging Source of Financial Information). Investor's Business Thursday, 02 May 2024 10:30
  • Unique Points
    • European Union plans to buy up to 36 million doses of Moderna’s Covid vaccine annually for at least four years.
    • Moderna retains its outlook for $4 billion in sales of respiratory vaccines, weighted to the back half of 2024.
    • Moderna could win FDA approval for its RSV vaccine later this quarter and launch it in the US this fall.
  • Accuracy
    • ]Moderna had a loss of $3.07 per share in Q1 2024, better than projected loss of $3.56 per share.[
    • Sales for Moderna were $167 million, higher than projected $93 million.
    • Moderna expects ‘higher vaccination uptake’ in the US if its updated Covid vaccine is available with the seasonal flu shot.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates

PharmiWeb.com Unknown AccessWire Thursday, 02 May 2024 13:48
  • Unique Points
    • Preparing for launches of RSV vaccine and Spikevax 2024-2025 formula
    • Three new clinical studies evaluating Moderna’s investigational individualized neoantigen therapy in combination with Merck’s Keytruda for treatment of patients with bladder cancer, kidney cancer and cutaneous squamous cell carcinoma initiated
    • Three new vaccine programs (Epstein-Barr virus, Varicella-Zoster virus, norovirus) advanced toward Phase 3 clinical trials
  • Accuracy
    • Expected product sales for 2024 are approximately $4 billion
    • Moderna expects U.S. approval for its vaccine against respiratory syncytial virus on May 12, with launch expected in the third quarter.
    • Moderna intends to file for approval of its flu vaccine with regulators this year.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (95%)
    The article contains some instances of inflammatory rhetoric and appeals to authority, but no formal or blatant logical fallacies are present. The author's statements about Moderna's financial results and business updates are factual and do not contain any false premises, invalid reasoning, or circular arguments.
    • ]As we anticipate the launches of our Spikevax 2024-2025 formula and RSV vaccine, we are exercising financial discipline[
    • ]"With 10 late-stage programs, and additional new programs advancing toward pivotal studies, we continue to expect numerous product milestones this year across our vaccines and therapeutics portfolio.[
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication